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Background: High levels of C-reactive protein (CRP), plasma lipoprotein (a) (Lp[a]) and homocysteine have been known to be risk factors for 
coronary artery disease. However, the prognostic value of these biomarkers on the long-term outcomes is limited after drug-eluting stents (DES) 
implantation.
Methods: We measured preprocedural levels of CRP, Lp [a] and homocysteine in 3,084 patients with successful DES implantation. The end points 
of the study were death, the composite of death and myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis. Logarithmic 
transformation was performed to normalize the distribution of the biomarkers.
Results: During follow-up (median, 3.7 years), 156 patients died, 57 had recurrent MI, 82 had stent thrombosis, and 424 had repeat 
revasculariztion. Patients who died or had MI had significant higher level of CRP (for death, 1.4±3.1 vs. 0.7±1.9 mg/dL, p=0.009, and for death/
MI, 1.3±2.9 vs. 0.7±1.9 mg/dL, p=0.006), Lp[a] (for death, 32.5±30.3 vs. 27.2±28.0 mg/dL, p=0.025, and for death/MI, 32.2±31.5 vs. 27.2±27.9 
mg/dL, p=0.029), and homocysteine (for death, 16.2±6.6 vs. 14.7±6.2 mg/dL, p=0.008, and for death/MI, 16.1±6.7 vs. 14.7±6.2 mg/dL, p=0.006) 
than those without these events. However, none of the biomarkers was related to increased risks of stent thrombosis and repeat revascularization. 
In Cox proportional-hazards models adjusting for clinical and procedural risk factors, CRP (for death; adjusted hazard ratio [HR], 1.7 per 1 SD 
increment in the log values, 95% confidence interval [CI] 1.31-2.22, p<0.001, and for death/MI; adjusted HR, 1.61, 95% CI 1.27-2.04, p<0.001) 
and Lp[a] (for death; adjusted HR, 1.53 per 1 SD increment in the log values, 95% CI 1.03-2.28, p=0.037, and for death/MI; adjusted HR, 1.55, 
95% CI 1.09-2.20, p=0.014) were independently predicted the risk of death or major cardiovascular event.
Conclusions: High preprocedural plasma level of CPR or Lp[a], but not homocystein, were the strong predictor of the increased risk for death and 
death/MI after successful DES implantation. However, none of biomarkers was associated with stent thrombosis and repeat revascularization.
